Nachrichten zur Bristol-Myers Squibb Co. Aktie

Why LianBio Stock Is Skyrocketing Today

Investors are loving LianBios new deal with Bristol Myers Squibb.…

Bristol-Myers Squibb: Time To Get Greedy

…

MRTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Mirati Therapeutics, Inc. to Bristol Myers Squibb

MONSEY, N.Y., Oct. 20, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating…

Is Bristol Myers Squibb Stock a Buy Now?

Bristol Myers Squibb recently announced an acquisition that should strengthen its oncology portfolio.…

Is Bristol Myers Squibb Stock a Buy Now? @themotleyfool #stocks $BMY

Bristol Myers Squibb recently announced an acquisition that should strengthen its oncology portfolio.…

Institutional Investors Dominate Bristol-Myers Squibb’s Shareholding Structure By Investing.com

Institutional Investors Dominate Bristol-Myers Squibb’s Shareholding Structure…

BUSINESS WIRE: Cellares gibt erweiterte Vereinbarung mit Bristol Myers Squibb bekannt, die ein zweites CAR-T Programm in das Technologieübernahme-Partnerschaftsprogramm von Cellares einbezieht

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.Im Rahmen dieser erweiterten Vereinbarung stellt Cellares…

BUSINESS WIRE: Cellares: estensione dellaccordo con Bristol Myers Squibb per includere un secondo programma CAR-T di partnership per ladozione della tecnologia Cellares

Questo report è stato trasmesso da Businesswire. Solo lazienda emittente è resposabile del suo contenuto.In base a tale accordo ampliato,…

The Zacks Analyst Blog Highlights Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer

Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer are part of the Zacks top Analyst Blog.…

BMS- und Mirati-Aktien sinken: Bristol Myers Squibb will Mirati Therapeutics übernehmen

Die Mirati-Aktionäre sollen 58 Dollar pro Aktie in bar erhalten, teilte der Pharmakonzern am Sonntag in New York mit. Zudem…

Bristol-Myers Squibb shells out $5.8B for Mirati: 5 big deal reports By Investing.com

Bristol-Myers Squibb shells out $5.8B for Mirati: 5 big deal reports…

Bristol-Myers Squibb to acquire Mirati in a deal worth up to $5.8 billion By Investing.com

Bristol-Myers Squibb to acquire Mirati in a deal worth up to $5.8 billion…

Movers & Shakers: Shares in weapons makers Lockheed Martin, RTX surge following surprise attack on Israel and other stocks on the move

Shares in RTX, Lockheed Martin, Marathon Oil, Occidental Petroleum, Mirati Therapeutics, and Bristol Myers Squibb Co. were on the move…

BMS- und Mirati-Aktien vorbörslich schwach: Bristol Myers Squibb will Mirati Therapeutics übernehmen

Die Mirati-Aktionäre sollen 58 Dollar pro Aktie in bar erhalten, teilte der Pharmakonzern am Sonntag in New York mit. Zudem…

BMS-Aktie: Bristol Myers Squibb will Mirati Therapeutics übernehmen

Die Mirati-Aktionäre sollen 58 Dollar pro Aktie in bar erhalten, teilte der Pharmakonzern am Sonntag in New York mit. Zudem…

US-Pharmakonzern BMS will für knapp 5 Milliarden Dollar zukaufen

NEW YORK (dpa-AFX) - Der US-Pharmakonzern Bristol Myers Squibb (BMS) will mit der Übernahme des Krebsmedikamentenherstellers Mirati Therapeutics für…

Bristol-Myers stärkt Krebsgeschäft mit Milliardenübernahme

Frankfurt (Reuters) - Der US-Pharmakonzern Bristol-Myers Squibb schluckt den Krebsspezialisten Mirati Therapeutics in einem bis zu 5,8 Milliarden Dollar schweren…

Bristol-Myers Squibb: Paukenschlag - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Bristol-Myers…

Paukenschlag: Bristol-Myers Squibb schluckt Mirati

Bereits in der vorangegangenen Handelswoche haben sich frische Übernahmegerüchte rund um den Präzisionsonkologie-Spezialisten Mirati Therapeutics gehalten. Konkret wurde Sanofi entsprechendes…

Paukenschlag: Bristol-Myers Squibb schluckt Mirati

Bereits in der vorangegangenen Handelswoche haben sich frische Übernahmegerüchte rund um den Präzisionsonkologie-Spezialisten Mirati Therapeutics gehalten. Konkret wurde Sanofi entsprechendes…

Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion

Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion…

: Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion

Mirati develops commercial-stage oncology therapies, and through the deal, Bristol Myers Squibb will add lung-cancer medicine Krazati, among others,…

Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal By Reuters

Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal…

Bristol Myers Squibb to acquire Mirati in a $4.8 billion deal

Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing $4.8 billion equity…

Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal

Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing $4.8 billion equity…

Bristol-Myers Squibb to acquire Mirati Therapeutics for $4.8B

…

Bristol-Myers Squibb: Kursziel gekürzt

London (www.aktiencheck.de) - Rating-Update: Carter Gould, Analyst von Barclays, stuft die Bristol-Myers Squibb-Aktie (ISIN: US1101221083, WKN: 850501, Ticker-Symbol: BRM, NYSE Ticker-Symbol:…

Eosinophilic Esophagitis Market to Show Positive Growth by 2032, Examines DelveInsight | Key Companies - Bristol Myers Squibb, Ellodi, AstraZeneca, Kyowa Kirin, Allakos, Pfizer, Revolo, EsoCap AG, NexEos Diagnostics, Celgene

The dynamics of the eosinophilic esophagitis market are anticipated to change in the coming years owing to the expected launch…

[Latest] Global Acute Myeloid Leukemia (AML) Therapeutics Market Size Envisioned at USD 2588.23 Million by 2030, Increasing a CAGR of 10.62% | Rising Investments by Pharmaceutical Giants

[230 + Pages Report] According to a market research study published by The Brainy Insights, the demand analysis of Global…

Prostate Health Market Size to Hit $ 82.64 Bn by 2032 | Rapid Advancements & Innovation in Prostate Health Treatments

[230+ Pages Report] According to a market research study published by The Brainy Insights, the demand analysis of Global…

IBD (Ulcerative Colitis and Crohns Disease) Treatment Market revenue to hit USD 36 Billion by 2033, says Research Nester

Leading IBD (Ulcerative Colitis and Crohns Disease) Treatment Market players include Bausch Health Companies Inc., AbbVie Inc., Novartis AG, Bristol…

Bristol-Myers Squibb meldet Dividende

Der amerikanische Pharmakonzern Bristol-Myers Squibb Co. (ISIN: US1101221083, NYSE: BMY) wird seinen Aktionären am 1. November 2023 eine vierteljährliche Dividende…

Bristol-Myers Squibb Company PFD CONV 2 declares $0.50 dividend

…

Bristol-Myers Squibb Company declares $0.57 dividend

…

Bristol-Myers Squibb Unusual Options Activity For August 21

read more...…

Bristol Myers (BMY) Announces Positive Updated NSCLC Data

Bristol Myers (BMY) repotrectinib shows durable efficacy benefits in patients with locally advanced or metastatic ROS1-Positive non-small cell lung cancer....…

Could Scientist Find Drug to Treat His Own Disease?

How a researchers 12-year journey to a new Bristol-Myers psoriasis medicine became personal: “You have hopes and daydreams almost in…

Bristol-Myers Squibb To Buyback $4 Bln Of Shares Under Accelerated Share Repurchase

NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Co. (BMY), a pharma major, said on Thursday that it has inked agreements…

Bristol Myers Sets $4 Billion Accelerated Stock Buyback >BMY

Bristol Myers Sets $4 Billion Accelerated Stock Buyback >BMY...…

Bristol Myers Squibb stock extends bounce after announced $4 billion accelerated buyback agreements

Shares of Bristol Myers Squibb Co. BMY got a 0.9% bump up in premarket trading Thursday, after the biopharmaceutical company…

Insiderhandel: EVP, Chief Research Officer verkauft Aktien von Bristol-Myers Squibb Company im Wert von 44.754$

Plenge, Robert M. - Vorstand - Tag der Transaktion: 2023-08-03...…

Should Dividend Investors Buy Bristol Myers Stock?

The drugmakers near future may be bumpy, but it has a brighter future on the horizon....…

Bristol-Myers Squibb Company PFD CONV 2 goes ex-dividend on Monday

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Squibb (BMY) Q2 2023 Earnings Call Transcript

BMY earnings call for the period ending June 30, 2023....…

Form 10-Q BRISTOL MYERS SQUIBB CO For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Meta Platforms, Comcast rise; Bristol-Myers, Sunnova fall, Thursday, 7/27/2023

Stocks that are trading heavily or have substantial price changes on Thursday: Meta Platforms, Comcast rise; Bristol-Myers, Sunnova fall...…

Compared to Estimates, Bristol Myers (BMY) Q2 Earnings: A Look at Key Metrics

The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended June 2023,…

UPDATE 2-Bristol Myers sales fall, cuts 2023 forecast as drugs face competition

...) By Michael Erman July 27 (Reuters) - Drugmaker Bristol Myers Squibb......…

Bristol Myers sales fall, cuts 2023 forecast as drugs face competition

...By Michael Erman (Reuters) -Drugmaker Bristol Myers Squibb......…

Bristol Myers Slashes Forecast on Tumbling Revlimid Sales

Cancer-fighting drugs Revlimid and Pomalyst drive a sales shortfall in the second quarter....…